PubMed Health⌕ Search

PubMed · 15267279

Electron attachment to PSCl3.

Abstract

Electron attachment to PSCl3 was studied in 133-Pa pressure of helium gas at temperatures from 298-550 K. Measurements of rate constants and branching fractions were made in a flowing-afterglow Langmuir-probe (FALP) apparatus. These experiments yielded an electron attachment rate constant of 5.1 x 10(-8) cm3 s(-1) that was found not to change significantly in the 298-550 K temperature range. This rate constant represents an attachment efficiency of about 14%. Attachment in 133 Pa of He gas yielded only the dissociative ion products PSCl2- and Cl-. The FALP data suggest that there is an activation energy of about 17 meV for production of PSCl2-. Attachment to PSCl3 was also studied at high pressure (9-93 kPa) of N2 in an ion mobility mass spectrometer, at 298 K. In contrast to the low-pressure data, the parent anion product channel (PSCl3-) was observed (along with the dissociative channels), and increased in importance with N2 pressure. Gaussian-3 (G3) calculations were carried out for PSCl3 and PSCl2 neutrals and anions to aid in interpretation of the experimental results. The calculations indicate that the electron affinity EA(PSCl2) is slightly smaller than EA(Cl), which may account for the observed branching fractions for PSCl2- and Cl- in the low-pressure experiments. A natural population analysis was performed to obtain the charges associated with each atom in the molecules in order to estimate how the attached electron is distributed. Comparison is made between the present study of electron attachment to PSCl3 and our earlier work on attachment to POCl3, and G3 calculations are reported here for neutral and anionic POCl2 and POCl3. In contrast to PSCl2, the calculations imply that EA(POCl2) is slightly greater than EA(Cl). For both PSCl3 and POCl3, the calculations show that the dissociative electron attachment process is close to thermoneutral.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W B Knighton, Thomas M Miller, E P Grimsrud, A A Viggiano. 2004-01-01. Electron attachment to PSCl3.. https://doi.org/10.1063/1.1630300

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗